Viridian Therapeutics, Inc. (VRDN) Balance Sheet

NASDAQ: VRDNAssets, liabilities, debt and equity over 10 years.

VRDN balance sheet, 2025

December 31, 2025 · U.S. dollars

$899.4M assets = $177.3M liabilities + $722.2M equity

What it owns$899.4MCash & ST investments: $874.7M (97.2%)Cash & ST investments$874.7M · 97%Other current: $19.6M (2.2%)PP&E: $3.6M (0.4%)Other non-current: $1.5M (0.2%)=How it is financed$899.4MCurrent liabilities: $70.7M (7.9%)Current liabilities $70.7MLong-term debt: $49.9M (5.6%)Other LT liabilities: $56.6M (6.3%)$56.6MShareholders’ equity: $722.2M (80.3%)Shareholders’ equity$722.2M · 80%

Both columns are drawn to the same scale: what VRDN owns equals what it owes plus shareholders’ equity. Hover a block for its value.

VRDN financial health

Debt / equity0.07
Low leverage · $0.07 of debt for each $1 of equity
Equity / assets80.3%
Equity-funded · of assets funded by shareholders
Cash / debt1,725.4%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles0.0%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

VRDN balance sheet trends, 2016–2025

Viridian Therapeutics, Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$4.3M2016$899.4M2025+81.3%/yr
Total liabilities$4.6M2016$177.3M2025+50.1%/yr
Shareholders’ equity−$326,0002016$722.2M2025—
Cash & short-term investments$3.3M2016$874.7M2025+85.6%/yr
Total debt$1.0M2016$50.7M2025+53.9%/yr
Net cash (debt)$2.3M2016$824.0M2025+$821.7M
Working capital−$326,0002016$823.5M2025+$823.9M
Book value per share$12.312022$8.522025−11.6%/yr
Debt / equity0.2620170.072025−0.19
Shares outstanding32.1M202284.8M2025+38.3%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

VRDN assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

VRDN liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

VRDN debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

VRDN balance sheet

Viridian Therapeutics, Inc. annual balance sheet
2025202420232022202120202019201820172016
Assets
Cash & short-term investments$874.7M$717.6M$477.4M$424.6M$197.0M$127.6M$26.8M$62.5M$47.4M$3.3M
Cash & equivalents$212.4M$99.6M$102.8M$155.6M$42.3M$45.9M$24.8M$32.6M$47.4M$3.3M
Short-term investments$662.3M$618.0M$374.5M$269.0M$154.7M$81.7M$2.0M$29.9M——
Receivables$0$0$102,000$102,000$451,000$0$108,000$24,000$1.5M$524,000
Inventory$0$0$0−$6.6M$0$0$0$0$1$64,000
Other current assets$19.6M$20.9M$9.0M$6.5M$2.7M$2.0M$2.8M$2.9M$3.0M$330,000
Total current assets$894.2M$738.5M$486.5M$424.6M$200.2M$129.6M$29.7M$65.4M$51.9M$4.3M
Property, plant & equipment (net)$3.6M$3.4M$3.3M$2.9M$2.1M$787,000$523,000$727,000$563,000$625,000
Goodwill & intangible assets$0$0$0$0$0$0$0$0$0$0
Long-term investments$0$0$0$0$0$0$0$0$0$0
Other non-current assets$1.5M$501,000$604,000$7.6M$1.5M$857,000$0$50,000$50,000$0
Total assets$899.4M$742.4M$490.4M$435.1M$203.7M$131.3M$30.3M$66.1M$52.5M$4.3M
Liabilities
Accounts payable$8.7M$2.1M$2.2M$14.2M$2.3M$670,000$1.1M$571,000$906,000$159,000
Short-term debt$753,000$513,000$843,000$613,000$520,000$455,000$4.0M$2.3M—$1.0M
Deferred revenue$367,000$288,000$288,000$288,000$289,000$301,000$5.0M$3.8M—$3.4M
Total current liabilities$70.7M$47.9M$26.6M$33.3M$13.6M$10.7M$10.2M$6.7M$3.9M$4.6M
Long-term debt$49.9M$20.6M$20.2M$4.6M$0$0$4.3M$8.0M$9.9M$0
Lease obligations$753,000$513,000$843,000$613,000$520,000$455,000————
Other long-term liabilities$56.6M$2.3M$1.6M$2.0M$2.4M$544,000$0$66,000$152,000$2.8M
Total liabilities$177.3M$70.8M$48.4M$40.0M$16.0M$11.2M$14.5M$14.8M$14.0M$4.6M
Shareholders' equity
Common stock & paid-in capital$1.0M$810,000$540,000$414,000$239,000$42,000$23,000$308,000$226,000$7,000
Retained earnings (deficit)−$1.34B−$995.9M−$725.9M−$488.2M−$358.3M−$278.9M−$168.2M−$126.3M−$93.6M−$30.6M
Accumulated other comprehensive income$447,000−$10,000$338,000−$390,000−$157,000−$8,000−$3.3M−$3,000−$2.8M$0
Total shareholders' equity$722.2M$671.6M$442.0M$395.1M$187.7M$120.0M$15.8M$51.3M$38.5M−$326,000
Key figures
Total debt$50.7M$21.1M$21.0M$5.3M$1.0M$455,000$8.3M$10.3M$9.9M$1.0M
Net cash (debt)$824.0M$696.5M$456.3M$419.3M$195.9M$127.2M$18.5M$52.2M$37.5M$2.3M
Working capital$823.5M$690.6M$459.8M$391.2M$186.5M$118.9M$19.6M$58.6M$48.0M−$326,000
Tangible book value$722.2M$671.6M$442.0M$395.1M$187.7M$120.0M$15.8M$51.3M$38.5M−$326,000
Book value per share$8.52$9.89$9.88$12.31——————
Shares outstanding84.8M67.9M44.8M32.1M——————
Current ratio12.6515.4318.2612.7314.6812.142.929.7113.310.93
Quick ratio12.3714.9917.9312.7314.4811.962.659.2812.550.84
Debt / equity0.070.030.050.010.010.000.530.200.26—
Equity / assets80.3%90.5%90.1%90.8%92.1%91.5%52.1%77.6%73.4%−7.7%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 26, 2026); data from EODHD.

VRDN financial position

At the end of fiscal 2025 (December 31, 2025), Viridian Therapeutics had total assets of $899.4 million (up 21.1% from a year earlier), total liabilities of $177.3 million and shareholders' equity of $722.2 million. It held $874.7 million in cash and short-term investments against $50.7 million of debt, a net cash position of $824.0 million. Its current ratio was 12.65. In the latest quarter (ended June 30, 2026) total assets were $1.1 billion and equity $662.1 million.

Related: VRDN income statement, VRDN cash flow statement, VRDN key metrics. See the VRDN stock overview for the latest quote and news.

VRDN balance sheet FAQ

What are Viridian Therapeutics's total assets?

Viridian Therapeutics reported total assets of $899.4 million at the end of fiscal 2025 (December 31, 2025), compared with $742.4 million a year earlier.

How much debt does Viridian Therapeutics have?

Viridian Therapeutics had $50.7 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.07.

How much cash does Viridian Therapeutics have?

Viridian Therapeutics held $874.7 million in cash and short-term investments at the end of fiscal 2025; with $50.7 million of debt that is net cash of $824.0 million.

What is Viridian Therapeutics's book value?

Viridian Therapeutics's shareholders' equity (book value) was $722.2 million at the end of fiscal 2025, or $8.52 per share.

What is Viridian Therapeutics's current ratio?

Viridian Therapeutics had current assets of $894.2 million and current liabilities of $70.7 million, a current ratio of 12.65 (it can cover its short-term obligations).

Biotechnology: balance sheet